181 related articles for article (PubMed ID: 35184335)
1. Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.
Koh Y; Nakano K; Katayama K; Yamamichi G; Yumiba S; Tomiyama E; Matsushita M; Hayashi Y; Yamamoto Y; Kato T; Hatano K; Kawashima A; Ujike T; Imamura R; Yamaguchi R; Imoto S; Shiotsu Y; Nonomura N; Uemura M
Int J Urol; 2022 May; 29(5):462-469. PubMed ID: 35184335
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
3. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Combination Therapy of Ipilimumab Plus Nivolumab for Non-clear Cell Renal Cell Carcinoma.
Bando Y; Furukawa J; Okamura Y; Hara T; Terakawa T; Nakano Y; Fujisawa M
Anticancer Res; 2022 Feb; 42(2):973-979. PubMed ID: 35093897
[TBL] [Abstract][Full Text] [Related]
5. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma.
Chehrazi-Raffle A; Muddasani R; Dizman N; Hsu J; Meza L; Zengin ZB; Malhotra J; Chawla N; Dorff T; Contente-Cuomo T; Dinwiddie D; McDonald BR; McDaniel T; Trent JM; Baehner FL; Murtaza M; Pal SK
JCO Precis Oncol; 2023 Apr; 7():e2200543. PubMed ID: 37027813
[TBL] [Abstract][Full Text] [Related]
6. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti-PD-1 Immune Checkpoint Inhibitors.
Salgia NJ; Bergerot PG; Maia MC; Dizman N; Hsu J; Gillece JD; Folkerts M; Reining L; Trent J; Highlander SK; Pal SK
Eur Urol; 2020 Oct; 78(4):498-502. PubMed ID: 32828600
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma.
Nemoto Y; Ishihara H; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Int Urol Nephrol; 2022 Jan; 54(1):47-54. PubMed ID: 34704214
[TBL] [Abstract][Full Text] [Related]
8. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
Gul A; Stewart TF; Mantia CM; Shah NJ; Gatof ES; Long Y; Allman KD; Ornstein MC; Hammers HJ; McDermott DF; Atkins MB; Hurwitz M; Rini BI
J Clin Oncol; 2020 Sep; 38(27):3088-3094. PubMed ID: 32491962
[TBL] [Abstract][Full Text] [Related]
9. SWI/SNF Complex Genomic Alterations as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Multiple Cancers.
Wang D; Wang J; Zhou D; Wu Z; Liu W; Chen Y; Chen G; Zhang J
Cancer Immunol Res; 2023 May; 11(5):646-656. PubMed ID: 36848524
[TBL] [Abstract][Full Text] [Related]
10. Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach.
Fiorentino M; Gruppioni E; Massari F; Giunchi F; Altimari A; Ciccarese C; Bimbatti D; Scarpa A; Iacovelli R; Porta C; Virinder S; Tortora G; Artibani W; Schiavina R; Ardizzoni A; Brunelli M; Knuutila S; Martignoni G
Oncotarget; 2017 Jan; 8(5):7328-7335. PubMed ID: 27741505
[TBL] [Abstract][Full Text] [Related]
11. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
12. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Negishi T; Nakagawa T; Nishiyama N; Kitamura H; Okajima E; Furubayashi N; Hori Y; Kuroiwa K; Son Y; Seki N; Tomoda T; Nakamura M
Jpn J Clin Oncol; 2022 Dec; 52(12):1430-1435. PubMed ID: 36093731
[TBL] [Abstract][Full Text] [Related]
13. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract][Full Text] [Related]
14. An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X; Vano Y; Helleux A; Su X; Lindner V; Davidson G; Mouawad R; Spano JP; Rouprêt M; Elaidi R; Compérat E; Verkarre V; Sun C; Chevreau C; Bennamoun M; Lang H; Tricard T; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Clin Cancer Res; 2023 Apr; 29(7):1279-1291. PubMed ID: 36374555
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.
Flippot R; Gorgeu V; Pujalte M; Colomba E; Alves C; Cerbone L; Carril L; Derosa L; Escudier B; Albigès L
Bull Cancer; 2022 May; 109(2S):2S31-2S38. PubMed ID: 35760468
[TBL] [Abstract][Full Text] [Related]
16. Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma.
Kim YJ; Kang Y; Kim JS; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park D; Park WY; Kang M
Sci Rep; 2021 Mar; 11(1):5600. PubMed ID: 33692449
[TBL] [Abstract][Full Text] [Related]
17. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
18. Radiomics can predict tumour response in patients treated with Nivolumab for a metastatic renal cell carcinoma: an artificial intelligence concept.
Khene ZE; Mathieu R; Peyronnet B; Kokorian R; Gasmi A; Khene F; Rioux-Leclercq N; Kammerer-Jacquet SF; Shariat S; Laguerre B; Bensalah K
World J Urol; 2021 Sep; 39(9):3707-3709. PubMed ID: 32632555
[No Abstract] [Full Text] [Related]
19. Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma.
Kotecha RR; Gedvilaite E; Ptashkin R; Knezevic A; Murray S; Johnson I; Shapnik N; Feldman DR; Carlo MI; Shah NJ; Dunigan M; Huberman K; Benayed R; Zehir A; Berger MF; Ladanyi M; Tsui DWY; Motzer RJ; Lee CH; Voss MH
JCO Precis Oncol; 2022 Jul; 6():e2200012. PubMed ID: 35797508
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
